Total Payments
$357,037
2024 Payments
$31,244
Companies
32
Transactions
203
Medicare Patients
1,503
Medicare Billing
$351,050
Payment Breakdown by Category
Consulting$274,473 (76.9%)
Research$45,279 (12.7%)
Travel$20,284 (5.7%)
Other$12,505 (3.5%)
Food & Beverage$4,397 (1.2%)
Education$99.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $274,473 | 96 | 76.9% |
| Unspecified | $45,279 | 20 | 12.7% |
| Travel and Lodging | $20,284 | 26 | 5.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,876 | 2 | 1.9% |
| Honoraria | $5,295 | 2 | 1.5% |
| Food and Beverage | $4,397 | 55 | 1.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $333.62 | 1 | 0.1% |
| Education | $99.00 | 1 | 0.0% |
Payments by Type
General
$311,758
183 transactions
Research
$45,279
20 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $75,478 | 35 | $0 (2024) |
| Celgene Corporation | $63,474 | 30 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $24,173 | 20 | $0 (2021) |
| AstraZeneca UK Limited | $21,920 | 7 | $0 (2024) |
| Gilead Sciences, Inc. | $20,232 | 18 | $0 (2021) |
| F. Hoffmann-La Roche AG | $19,653 | 7 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $12,977 | 8 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $12,487 | 4 | $0 (2022) |
| PFIZER INC. | $12,287 | 10 | $0 (2024) |
| ABBVIE INC. | $12,214 | 8 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,244 | 15 | Genentech, Inc. ($13,300) |
| 2023 | $31,644 | 21 | Genentech, Inc. ($17,840) |
| 2022 | $59,453 | 34 | Genentech, Inc. ($9,240) |
| 2021 | $40,929 | 16 | Genentech, Inc. ($15,015) |
| 2020 | $37,068 | 14 | Karyopharm Therapeutics Inc. ($9,137) |
| 2019 | $59,273 | 33 | Celgene Corporation ($35,786) |
| 2018 | $51,409 | 34 | F. Hoffmann-La Roche AG ($16,518) |
| 2017 | $46,017 | 36 | Bayer HealthCare Pharmaceuticals Inc. ($8,966) |
All Payment Transactions
203 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $132.76 | General |
| 12/09/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| 12/02/2024 | Genentech, Inc. | Actemra (Biological), Lunsumio | — | Cash or cash equivalent | $3,960.00 | Research |
| Study: Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma • Category: Immunology | ||||||
| 10/02/2024 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,960.00 | General |
| 08/13/2024 | PFIZER INC. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,160.00 | General |
| Category: Oncology | ||||||
| 08/09/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| Category: Oncology | ||||||
| 07/15/2024 | PFIZER INC. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $192.99 | General |
| Category: Oncology | ||||||
| 06/05/2024 | Genentech USA, Inc. | Lunsumio (Biological), Columvi, Polivy | Consulting Fee | Cash or cash equivalent | $2,850.00 | General |
| Category: BioOncology | ||||||
| 05/29/2024 | Genentech, Inc. | Actemra (Biological), Lunsumio | — | Cash or cash equivalent | $2,310.00 | Research |
| Study: Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma • Category: Immunology | ||||||
| 04/05/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| Category: Oncology | ||||||
| 04/03/2024 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,310.00 | General |
| 03/12/2024 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $760.00 | General |
| 03/08/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,202.50 | General |
| 03/08/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $440.50 | General |
| 01/18/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 12/19/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: Oncology | ||||||
| 12/14/2023 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $118.15 | General |
| 12/14/2023 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $76.49 | General |
| 12/09/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $120.16 | General |
| 11/14/2023 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: Heart Failure | ||||||
| 11/14/2023 | MorphoSys, US Inc. | MONJUVI (Drug) | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: Oncology | ||||||
| 11/02/2023 | Genentech, Inc. | Actemra (Biological), Lunsumio | — | Cash or cash equivalent | $2,970.00 | Research |
| Study: Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma • Category: Immunology | ||||||
| 10/04/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| 09/06/2023 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,970.00 | General |
| 08/18/2023 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | Genentech, Inc. | $15,420 | 5 |
| A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma (CC-5013-NHL-007) | Celgene Corporation | $10,205 | 1 |
| A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma | Biotest Pharmaceuticals Corporation | $5,200 | 3 |
| CC-5013-NHL-007 - A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lympho | Celgene Corporation | $4,275 | 1 |
| PHASE 3 MOSUNETUZUMAB LENALIDOMIDE IN R R FOLLICULAR LYMPHOMA | Genentech, Inc. | $3,630 | 2 |
| A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma | BIOTEST AG | $1,900 | 2 |
| CC-486-DLBCL-001 | Celgene Corporation | $1,463 | 1 |
| A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma | ABBVIE INC. | $1,100 | 1 |
| CC-122-DLBCL-001 - A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | Celgene Corporation | $1,082 | 1 |
| Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma (CC-5013-DLC-002) | Celgene Corporation | $476.00 | 1 |
| CC-486-DLBCL-001 - (AZA-JMML-001) PhII Azacitidine Open-label PK, Pharmacodynamics, Safety, Activity vs Historical Controls in Peds With ND Advanced MDS | Celgene Corporation | $442.00 | 1 |
| A phase I open label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2816126 in subjects with relapsed refractory diffuse large B cell lymphoma, transformed follicular lymphoma, other Non Ho | GlaxoSmithKline, LLC. | $85.96 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 302 | 610 | $279,350 | $55,942 |
| 2022 | 5 | 372 | 748 | $289,885 | $74,214 |
| 2021 | 5 | 457 | 949 | $278,565 | $122,370 |
| 2020 | 5 | 372 | 829 | $245,525 | $98,525 |
Total Patients
1,503
Total Services
3,136
Medicare Billing
$351,050
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 197 | 392 | $166,600 | $31,671 | 19.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 61 | 167 | $91,850 | $20,020 | 21.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 14 | 14 | $9,800 | $2,325 | 23.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 30 | 37 | $11,100 | $1,927 | 17.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 187 | 370 | $141,015 | $29,128 | 20.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 83 | 205 | $101,730 | $25,896 | 25.5% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 21 | 72 | $11,520 | $11,493 | 99.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 58 | 78 | $20,320 | $3,992 | 19.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 23 | 23 | $15,300 | $3,704 | 24.2% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 55 | 314 | $50,240 | $50,428 | 100.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 129 | 231 | $78,540 | $24,928 | 31.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 55 | 140 | $63,700 | $21,587 | 33.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 75 | 81 | $27,540 | $7,436 | 27.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 80 | 101 | $23,230 | $7,205 | 31.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 28 | 47 | $21,385 | $6,483 | 30.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 14 | 14 | $9,100 | $2,969 | 32.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 21 | 21 | $4,830 | $1,333 | 27.6% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 49 | 262 | $41,920 | $41,889 | 99.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 142 | 257 | $87,380 | $23,972 | 27.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 55 | 153 | $69,615 | $19,659 | 28.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 101 | 132 | $30,360 | $8,094 | 26.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 25 | 25 | $16,250 | $4,911 | 30.2% |
About Dr. John Leonard, MD
Dr. John Leonard, MD is a Internal Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992892079.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Leonard, MD has received a total of $357,037 in payments from pharmaceutical and medical device companies, with $31,244 received in 2024. These payments were reported across 203 transactions from 32 companies. The most common payment nature is "Consulting Fee" ($274,473).
As a Medicare-enrolled provider, Leonard has provided services to 1,503 Medicare beneficiaries, totaling 3,136 services with total Medicare billing of $351,050. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Medical Oncology
- Location New York, NY
- Active Since 10/09/2006
- Last Updated 09/19/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1992892079
Products in Payments
- CALQUENCE (Drug) $32,642
- Revlimid (Drug) $32,451
- GAZYVA (Biological) $16,518
- Actemra (Biological) $15,420
- Aliqopa (Drug) $11,658
- Rituxan (Biological) $10,121
- XPOVIO (Drug) $9,137
- Non-Covered $8,937
- IMBRUVICA (Drug) $8,149
- Non-Covered Product (Drug) $7,920
- BT062 (Drug) $7,100
- VENCLEXTA (Biological) $5,672
- KYMRIAH (Biological) $5,502
- KEYTRUDA (Biological) $5,000
- RITUXIMAB (Drug) $4,716
- ADCETRIS (Biological) $4,699
- BRUKINSA (Drug) $4,550
- VENCLEXTA (Drug) $3,837
- Lunsumio (Biological) $2,850
- OPDIVO (Biological) $2,400
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New York
Dr. Stephen Saletan, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Michael Schuster, Md, MD
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Dr. Ziad Ali, Md Dphil, MD DPHIL
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Dr. James Underberg, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Ricky Hsu, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Gail Roboz, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M